Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| CrowdStrike | Powerchip Semiconductor Manufacturing Corporation | Pfizer | |
|---|---|---|---|
| Moat rating | narrow Narrow rather than wide because the FY2026 10-K argues both ways and its own risk factors are the harder side: it describes a self-reinforcing data advantage and says "we do not believe any of our competitors currently have a true platform offering equivalent to the Falcon platform", but the same filing calls the market for security and IT operations solutions "intensely competitive, fragmented", warns that "Competitive pricing pressure may reduce our gross profits", and still carries the July 19 Incident as having "had, and is expected to continue to have, an adverse effect on our business, sales, customer and partner relations, reputation" more than two years after it occurred. | none PSMC lost money through the last mature-node downturn and then sold its newest fab. Its 2025 annual report (printed 2026-02-24) records revenue of NT$46.7 billion and 'a net loss after tax of NT$7.8 billion for the year'. Gross profit swung from NT$525,425 thousand in 2024 to a loss of NT$1,536,997 thousand in 2025, 'primarily attributable to an increase in gross loss from operations at the Tongluo Fab'. The report says 'good performance was difficult both in pricing and capacity utilization rates for mature-node wafer foundry services'. PSMC then agreed to sell the Tongluo site and facilities, excluding manufacturing equipment, to Micron. The Register (2026-01-20) reports total cash consideration of US$1.8 billion, against PSMC's earlier statement that it had invested more than NT$300 billion (US$9.5 billion) in the facility. Profits have since recovered: Q2 2026 net income was NT$3,291 million, against a NT$3,334 million loss a year earlier, per the company's September 2026 presentation. The cited sources tie that recovery to memory and wafer price increases, not to a lasting edge. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | network effects The 10-K states the mechanism directly: "The more data that is fed into our Falcon platform, the more intelligent the AI Security Cloud becomes, the stronger our ability to anticipate and counter evolving adversary tradecraft, and the more our customers benefit, creating a powerful network effect that increases the overall value we provide." | none The cited evidence supports none of the candidate moat sources. Cost: the annual report says its 12-inch aluminum-interconnect dies cost 30% less than 8-inch dies at the same node, yet the company still posted a 2025 gross loss. Switching costs: the report names 'the price and capacity competition of china wafer foundries' as an unfavorable factor. TrendForce (2026-05-07) says customers in HV processes and CIS applications are 'increasingly turning to Chinese foundries for more stable pricing and capacity availability'. Niche memory: PSMC's September 2026 presentation claims shares of 71% in DRAM (≤1Gb) and 74% in pseudo SRAM (≤256Mb), citing 'Company data, Omdia, TrendForce'. No independent source confirming those shares was found. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader Co-leader rather than clear leader because the only claim of platform primacy available is the company's own ("we do not believe any of our competitors currently have a true platform offering equivalent"), while the same 10-K describes a fragmented market and lists seven distinct categories of competitor, from legacy antivirus to network security, cloud security, identity and legacy SIEM vendors. | at parity PSMC sits in a cluster of similar-sized foundries rather than leading any. TrendForce ranks it tenth in 1Q26 (foundry-only revenue of $386 million, a 0.8% share) and tenth in 2Q26 ($432 million). It is just behind Nexchip ($447 million), VIS ($451 million) and Tower ($460 million). Its own annual report puts it 'among the top ten wafer foundry companies worldwide, with a market share of approximately 1%'. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate The 10-K's risk factors state that "Competitive pricing pressure may reduce our gross profits" and that competing successfully may require "aggressive pricing", which is the company's own case against strong pricing power; the offsetting factor it cites is module consolidation on one sensor. | weak PSMC is raising prices now, but on a memory shortage after a year of gross losses. The 2025 annual report shows a gross loss of NT$1,536,997 thousand. TrendForce (2026-04-22, citing Liberty Times) reports that PSMC 'sharply raised DRAM foundry pricing in March', raised NAND wafer start prices in April, and lifted 8-inch prices 'by an average of around 10% month over month since March'. President Martin Chu said logic price increases 'are likely to remain far more moderate than the sharp hikes seen in memory'. He tied the memory upswing to 'a structural supply deficit through the second half of 2026', which is a cyclical driver. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | A single lightweight sensor collects enterprise data once and reuses it across 33 cloud modules, and the pooled telemetry trains the models every customer is then defended by — the 10-K calls this crowdsourced, high-fidelity data "cloud-scale AI" and treats it as the fundamental differentiator from competitors. | PSMC is a Taiwanese foundry with two 8-inch and three 12-inch fabs in Hsinchu and Zhunan. It has three businesses: memory foundry (niche DRAM, SLC NAND and NOR flash), specialty logic (PMICs, power discretes, high-voltage display drivers, CMOS image sensors) and a newer '3D AI foundry' (wafer-on-wafer stacking, interposers, silicon capacitors and HBM post-wafer finishing). In Q2 2026, memory was 52% of revenue, logic 42.6% and 3D AI 5.4%, per its September 2026 presentation. 2025 was a loss year. Revenue rose 4% to NT$46.7 billion, but the company lost NT$7.8 billion as the new Tongluo fab failed to reach scale. 2026 has turned on prices. Q2 2026 revenue was NT$17,291 million, up 53% YoY, with foundry utilization of 87% against 75% a year earlier. TrendForce ranks PSMC tenth in 2Q26 with $432 million, noting that 'overall shipments increased only modestly' and that price increases drove the growth. The strategy is changing. PSMC sold the Tongluo site to Micron, and will provide HBM post-wafer finishing for Micron, with mass production expected in Q4 2027 (TrendForce, 2026-04-22). Its silicon capacitors are expected in Intel's EMIB packaging, according to PSMC. The verdict is no moat. PSMC is a mature-node foundry whose 2026 profits reflect a memory-price cycle after a loss-making 2025, and Chinese foundries compete with it on price. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | AI-native security platform — an adopter and reseller of AI rather than a supplier of AI infrastructure. | Upstream foundry for fabless memory and specialty-logic designers. Fabless customers were 90% of Q2 2026 sales. It also provides silicon capacitors, interposers and HBM post-wafer finishing to AI packaging supply chains. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |